AR077498A1 - Proceso para producir derivados de fluorocitidina - Google Patents

Proceso para producir derivados de fluorocitidina

Info

Publication number
AR077498A1
AR077498A1 ARP100102691A ARP100102691A AR077498A1 AR 077498 A1 AR077498 A1 AR 077498A1 AR P100102691 A ARP100102691 A AR P100102691A AR P100102691 A ARP100102691 A AR P100102691A AR 077498 A1 AR077498 A1 AR 077498A1
Authority
AR
Argentina
Prior art keywords
formula
compound
fluorocitidine
derivatives
produce
Prior art date
Application number
ARP100102691A
Other languages
English (en)
Inventor
Tsung-Cheng Hu
Hong-Tsung Huang
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of AR077498A1 publication Critical patent/AR077498A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicacion 1: Un proceso para preparar un compuesto purificado de formula (1), donde R3 es alquilo, cicloalquilo, aralquilo, arilo, o alcoxi, caracterizado porque comprende: (a) hacer reaccionar un compuesto de la formula (2), donde cada de R1 y R2 representa en forma independiente un grupo protector de hidroxilo, con un agente de acilacion de formula: X-C(=O)-R3, donde X es un grupo activante de acilo y R3 es como se define precedentemente, en un solvente orgánico para dar un compuesto acilado de formula (3), donde cada de R1, R2, y R3 es como se define precedentemente; (b) desproteger el compuesto acilado de formula (3) para obtener el compuesto de formula (1); y (c) disolver el compuesto de formula (1) con un unico solvente o una mezcla de solventes; y (d) sembrar con un compuesto substancialmente puro de formula (1). Reivindicacion 11: Capecitabina caracterizado porque el tamano promedio de partícula D90 es 250 a 350 mm, D50 es 100 a 120 mm y D10 es 25 a 30 mm.
ARP100102691A 2009-07-23 2010-07-23 Proceso para producir derivados de fluorocitidina AR077498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22797109P 2009-07-23 2009-07-23

Publications (1)

Publication Number Publication Date
AR077498A1 true AR077498A1 (es) 2011-08-31

Family

ID=43497887

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102691A AR077498A1 (es) 2009-07-23 2010-07-23 Proceso para producir derivados de fluorocitidina

Country Status (8)

Country Link
US (1) US20110021769A1 (es)
EP (1) EP2456778A4 (es)
JP (1) JP2012533618A (es)
KR (1) KR20120037932A (es)
CN (1) CN102858791A (es)
AR (1) AR077498A1 (es)
TW (1) TW201103550A (es)
WO (1) WO2011010967A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103059085B (zh) * 2011-12-27 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 一种抗癌药物中间体及其制备方法
CN103183713B (zh) * 2011-12-31 2015-08-05 沈阳药科大学 5-脱氧-d-呋喃核糖氧苷类化合物的制备方法
CN103910773B (zh) * 2014-04-08 2015-11-25 宁波美诺华药业股份有限公司 卡培他滨杂质的合成方法
CN104628804A (zh) * 2015-01-30 2015-05-20 吉林修正药业新药开发有限公司 一种卡培他滨杂质乙酰缩合物的合成方法
CN106496294B (zh) * 2016-09-21 2018-10-30 齐鲁天和惠世制药有限公司 一种制备微粉型卡培他滨的方法
CN107936075A (zh) * 2017-12-28 2018-04-20 山东铂源药业有限公司 一种卡培他滨中间体的合成方法
CN109651466A (zh) * 2018-12-20 2019-04-19 深圳市祥根生物科技有限公司 卡培他滨杂质g的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
JP2010524960A (ja) * 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법

Also Published As

Publication number Publication date
JP2012533618A (ja) 2012-12-27
KR20120037932A (ko) 2012-04-20
EP2456778A4 (en) 2013-05-29
US20110021769A1 (en) 2011-01-27
EP2456778A1 (en) 2012-05-30
TW201103550A (en) 2011-02-01
WO2011010967A1 (en) 2011-01-27
CN102858791A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
AR077498A1 (es) Proceso para producir derivados de fluorocitidina
CY1124429T1 (el) Ενωσεις oi οποιες τροποποιουν τον υποδοχεα ανδρογονου
RU2020113165A (ru) Циклические пуриновые динуклеотиды в качестве модуляторов sting
ES2579175T3 (es) Proceso para la producción de intermediarios de estetrol
AR092835A1 (es) Compuestos de d-aminoacido para enfermedades del higado
ES2677919T3 (es) Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
CU24316B1 (es) Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen
CO6210821A2 (es) Metodo para la produccion de clorhidrato de prasugrel de lata pureza
ES2670878T3 (es) Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa
PE20142360A1 (es) Procesos e intermediarios para preparar un inhibidor de jak
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
PH12014501719A1 (en) Pyridone derivatives
JP2009143956A5 (es)
CR20190244A (es) Agentes control de plaga
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
CO6020004A1 (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
PE20091010A1 (es) Derivados de tetrahidroquinolina
EP3388426A3 (en) Compounds for protection of cells
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
BR112014028692A2 (pt) processo para a preparação de compostos de 2-deoxi-2- fluoro-2-metil-d-ribofuranosil nucleosídeo
CY1122518T1 (el) Καινοφανεις προσδετες υποδοχεα οιστρογονου
NZ707276A (en) Compounds useful in the synthesis of benzamide compounds
CY1115933T1 (el) Διϋποκατεστημενες ενωσεις τετραϋδροφουρανυλιου ως ανταγωνιστες toy β1-υποδοχεα βραδυκινινης

Legal Events

Date Code Title Description
FB Suspension of granting procedure